Loading stock data…
LLY
$967.93+4.60 (+0.48%)
Pre-Market$966.20-1.73 (-0.18%)· Last close May 4
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eli Lilly and Company in the Healthcare sector is trading at $967.93. The stock is currently 15% below its 52-week high of $1,133.95, remaining 6.3% above its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why LLY maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$967.93
Potential Downside
29.3%
Whystock Fair Value$684.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus29 analysts
Buy
Mean target$1202+24.2%
Range$850.00 – $1500
Fundamentals
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$824.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.17
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Strong income play. Yield provides a meaningful total return floor.
69.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
52.01%
Volume
Today's trading volume
3.13M
Recent News
Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises
Competition from Eli Lilly puts pressure on margins despite strong early uptake
Novo Nordisk’s Weight-Loss Pill Momentum Faces Pricing Pressure
Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.
3 Reasons It's Not Too Late to Buy Eli Lilly Stock
The company still has a strong lead in its core therapeutic area.
Novo Nordisk Obesity Pill Momentum Meets Valuation Gap And Risk Flags
Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...
Eli Lilly Annual Meeting: Directors Win, Governance Changes Fail as Ricks Touts 45% Revenue Jump
Eli Lilly and Company (NYSE:LLY) held its 2026 annual meeting of shareholders virtually, with Vice President of Sustainability Jim Greffet moderating and Chair, President, and CEO Dave Ricks leading the formal business and post-vote remarks. Greffet opened the meeting with standard notices about for